It is also known that EGFR mutations activated the antiapoptotic protein Akt (Sordella et al, 2004), and that patients whose tumours have activated Akt are more sensitive to TKIs than patient whose tumours are phospho-AKT negative (Cappuzzo et al, 2004). This evidence concerns the gene AKT1 and neoplasm.